ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Progress toward a Staphylococcus aureus vaccine.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 165 citations in OpenAlex.
- Role and plasticity of Th1 and Th17 responses in immunity toHuman vaccines & immunotherapeutics · 2019Trial
- Efficacy of a polyvalent mastitis vaccine against Staphylococcus aureus on a dairy Mediterranean buffalo farm: results of two clinical field trials.BMC veterinary research · 2017Trial
- Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.Human vaccines & immunotherapeutics · 2015Trial
- Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Human vaccines & immunotherapeutics · 2015Trial
- Prevalence of chlorhexidine-resistant methicillin-resistant Staphylococcus aureus following prolonged exposure.Antimicrobial agents and chemotherapy · 2014Trial
- Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.Clinical and vaccine immunology : CVI · 2012Trial
- Repurposing lusutrombopag: unveiling anti-Staphylococcus aureus activity in a novel oral thrombopoietin receptor agonist.BMC microbiology · 2026Article
- A promisingClinical and experimental vaccine research · 2025Review
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Electron-Beam-KilledVaccines · 2024Article
- Staphylococcal mastitis in dairy cows.Frontiers in veterinary science · 2024Review
- Challenges in development of vaccines directed toward antimicrobial resistant bacterial species.Human vaccines & immunotherapeutics · 2023Review
- Organotypic 3D Co-Culture of Human Pleura as a Novel In Vitro Model ofBioengineering (Basel, Switzerland) · 2023Article
- Designing a Next-Generation Multiepitope-Based Vaccine againstPathogens (Basel, Switzerland) · 2023Article
- Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Synthesis and Glycosidation of Anomeric Halides: Evolution from Early Studies to Modern Methods of the 21st Century.Chemical reviews · 2022Review
- Impaired T-Lymphocyte Responses During Childhood Staphylococcus aureus Infection.The Journal of infectious diseases · 2022Observational
- Natural Human Immunity Against Staphylococcal Protein A Relies on Effector Functions Triggered by IgG3.Frontiers in immunology · 2022Article
- Development of a Conserved Chimeric Vaccine for Induction of Strong Immune Response againstVaccines · 2021Article
- (Automated) Synthesis of Well-defined Staphylococcus Aureus Wall Teichoic Acid Fragments.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
High attack rates and the ability of Staphylococcus aureus to develop resistance to all antibiotics in medical practice heightens the urgency for vaccine development. S. aureus causes many disease syndromes, including invasive disease, pneumonia, and skin and soft tissue infections. It remains unclear whether a single vaccine could protect against all of these. Vaccine composition is also challenging. Active immunization with conjugated types 5 and 8 capsular polysaccharides, an iron scavenging protein, isdB, and passive immunization against clumping factor A and lipoteichoic acid have all proven unsuccessful in clinical trials. Many experts advocate an approach using multiple antigens and have suggested that the right combination of antigens has not yet been identified. Others advocate that a successful vaccine will require antigens that work by multiple immunologic mechanisms. Targeting staphylococcal protein A and stimulating the T-helper 17 lymphocyte pathway have each received recent attention as alternative approaches to vaccination in addition to the more traditional identification of opsonophagocytic antibodies. Many questions remain as to how to successfully formulate a successful vaccine and to whom it should be deployed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.